arrow
G

Gurbakhash Kaur

Tisch Cancer Institute
H指数:17
被引数:1,266

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: BRIDGE−2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians

更正:BRIDGE−2M:优化多发性骨髓瘤患者CAR-T治疗前桥接治疗:美国医师修改的双盲德尔菲专家组

2026-09-280
OAAI
BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians

BRIDGE-2M:优化多发性骨髓瘤CAR-T治疗前桥接治疗:美国医师改良双盲德尔菲专家组的评估

2026-08-190
OAAI
Polymorphic IGLV6-57 AL amyloid fibrils and features of a shared folding pathway

多晶型 IGLV6-57 AL 淀粉样蛋白纤维及其共享折叠途径的特征

2026-07-230
OAAI
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response

多发性骨髓瘤患者对特克替玛初始无应答后延迟应答的预测因子

2025-10-110
OAAI
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium

氟达拉滨淋巴细胞清除暴露与伊达比特-维克鲁塞尔治疗后复发性/难治性多发性骨髓瘤的毒性相关:来自美国骨髓瘤免疫治疗联盟的真实世界经验

2025-09-170
PREAI
Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

前瞻性真实世界评估t(11;14)在多发性骨髓瘤中的患病率及疾病生物学:MEDICI研究分析

2025-08-210
OAAI
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

接受过BCMA靶向疗法的复发/难治性多发性骨髓瘤患者中teclistamab的治疗效果:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-06-250
OAAI
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the US Multiple Myeloma Immunotherapy Consortium

复发难治性多发性骨髓瘤(RRMM)老年患者接受teclistamab治疗后的结局:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-05-090
OA
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma

CC-98633/BMS-986354(B细胞成熟抗原[BCMA] NEX-T®嵌合抗原受体[CAR] T细胞疗法)在经三药类治疗暴露的多发性骨髓瘤患者中的I期临床试验

LEUKEMIA
IF13.4
2025-02-051
OA
Dexamethasone Is Associated with Cataracts in Multiple Myeloma Even after Adjusting for Age: Results of a Large Cross-Sectional Survey

地塞米松与多发性骨髓瘤患者并发白内障相关,即使在调整年龄因素后:一项大规模横断面调查的结果

BLOOD
IF23.1
2024-11-050
PRE
Screening for AL Amyloidosis in Smoldering Multiple Myeloma

对冒烟型多发性骨髓瘤进行AL型淀粉样变性筛查

BLOOD
IF23.1
2024-11-050
PRE
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: US Myeloma Immunotherapy Consortium Real- World Experience

接受Idecabtagene Vicleucel治疗的多发性骨髓瘤患者的绝对淋巴细胞计数和结局: 美国骨髓瘤免疫疗法联盟的真实世界经验

2024-08-011
OAAI
Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy

治疗性血浆置换治疗多发性骨髓瘤铸型肾病的疗效

2024-06-142
PRE